«A major step forward»

The CDK4/6 inhibitor ribociclib (Kisqali^®) for the treatment of HR+/HER2- metastatic breast cancer consistently showed a significant increase in OS (1-4). What does this mean for clinical practice? In a recent discussion between three Swiss breast cancer experts, Prof. Thomas Ruhstaller, Prof. Christian Kurzeder and Dr. Khalil Zaman, ribociclib distinguished itself as a therapy of first choice.